Targeting a specific enzyme to fight urinary tract infections
Targeting cytochrome bd as an anti-biofilm strategy
This study is exploring a new way to help people with recurring urinary tract infections by targeting a specific part of the bacteria that causes these infections, which could lead to better treatments for those affected.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-10902102 on NIH RePORTER |
What this research studies
This research focuses on developing a new strategy to combat urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC). The approach involves inhibiting the respiration of UPEC, which is crucial for their survival and ability to form protective biofilms in the bladder. By targeting a specific enzyme called cytochrome bd, the research aims to disrupt the bacteria's ability to evade the immune system and resist antibiotics. This could lead to more effective treatments for patients suffering from recurrent UTIs.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who experience recurrent urinary tract infections, particularly those caused by uropathogenic E. coli.
Not a fit: Patients with UTIs caused by non-uropathogenic bacteria or those who do not have recurrent infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively prevent and treat urinary tract infections, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in targeting bacterial respiration as a strategy to combat infections, indicating potential success for this novel approach.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Hadjifrangiskou, Maria — Vanderbilt University Medical Center
- Study coordinator: Hadjifrangiskou, Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.